What question did this study set out to answer?

To evaluate the efficacy and safety of paroxetine treatment in individuals with social anxiety disorder.

September 1, 1999Acta Psychiatrica Scandinavica

Paroxetine in social anxiety disorder: a randomized placebo‐controlled study

View Full Paper

Ask AI

Bookmark

Authors

CAChrister AllgulanderUppsala University

Discussion

Member takes

Overview

Randomized double-blind trial shows paroxetine reduces symptoms and avoidance behaviour in social anxiety disorder, indicating its clinical efficacy despite treatment-related adverse effects.

Key Points

To evaluate the efficacy and safety of paroxetine treatment in individuals with social anxiety disorder.
Randomized, double-blind, placebo-controlled trial evaluating paroxetine (20–50 mg daily) versus placebo over 3 months.
Included previously undiagnosed and untreated participants with generalized social phobia recruited via newspaper advertisements.
Outcomes assessed included self-rated social anxiety, avoidance behavior, and clinician-rated global improvement.
Intent-to-treat analysis (paroxetine n=44, placebo n=48) revealed significant improvements in efficacy outcomes starting at 4–6 weeks and increasing throughout the 3-month period.
Nine participants receiving paroxetine discontinued treatment due to adverse events compared to 3 participants receiving placebo.
Sexual side effects were reported by 18 participants on paroxetine compared to 4 participants on placebo.

Cite This Study

Christer Allgulander (1999) studied this question.

synapsesocial.com/papers/6a1d2a8b73c56dd1bd2f4d0a https://doi.org/10.1111/j.1600-0447.1999.tb10845.x

View Full Paper

Ask AI

Bookmark

September 1, 1999Acta Psychiatrica Scandinavica

Paroxetine in social anxiety disorder: a randomized placebo‐controlled study

View Full Paper

Ask AI

Bookmark

Authors

CAChrister AllgulanderUppsala University

Discussion

Member takes

Overview

Randomized double-blind trial shows paroxetine reduces symptoms and avoidance behaviour in social anxiety disorder, indicating its clinical efficacy despite treatment-related adverse effects.

Key Points

To evaluate the efficacy and safety of paroxetine treatment in individuals with social anxiety disorder.
Randomized, double-blind, placebo-controlled trial evaluating paroxetine (20–50 mg daily) versus placebo over 3 months.
Included previously undiagnosed and untreated participants with generalized social phobia recruited via newspaper advertisements.
Outcomes assessed included self-rated social anxiety, avoidance behavior, and clinician-rated global improvement.
Intent-to-treat analysis (paroxetine n=44, placebo n=48) revealed significant improvements in efficacy outcomes starting at 4–6 weeks and increasing throughout the 3-month period.
Nine participants receiving paroxetine discontinued treatment due to adverse events compared to 3 participants receiving placebo.
Sexual side effects were reported by 18 participants on paroxetine compared to 4 participants on placebo.

Cite This Study

Christer Allgulander (1999) studied this question.

synapsesocial.com/papers/6a1d2a8b73c56dd1bd2f4d0a https://doi.org/10.1111/j.1600-0447.1999.tb10845.x

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark